Gsk Plc-spon Adr.

Organisation

79 New Oxford Street, London, United Kingdom, WC1A 1DG

Headquarters

66841

Employees

Health Technology

Industry

Emma Walmsley

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.

Price

Target

Gsk Plc-spon Adr. (GSK) Price vs Consensus Price Target

As per the chart shown above, analysts believe that the Gsk Plc-spon Adr. (GSK) share price will touch around $57.48 in next 12-months.

Currently 33 wall-street analysts regularly analyze the financials of Gsk Plc-spon Adr. on a frequent basis to provide recommendations along with target share price. 33 analysts offering 12-month price forecasts for Gsk Plc-spon Adr. (GSK) have a share price target of $57.48. This median of share price forecast represents a 1.39% upside from the latest price of $56.69 as on 04.04.26.

Gsk Plc-spon Adr. (GSK) Share Price Forecast

Home

US Stocks

Gsk Plc-spon Adr. (GSK)

Gsk Plc-spon Adr. Stock Forecast

Gsk Plc-spon Adr. Stock Forecast & Price Target (Analyst Recommendation) | INDmoney

Percentage Difference

Gsk Plc-spon Adr. (GSK): Difference between Current Price & Median Forecasted Price

Below is a chart showing the percentage difference between Gsk Plc-spon Adr.'s share price and its median forecast price. As on 04.04.26, the difference is -2.59%

Gsk Plc-spon Adr. Forecast and Target Price

Gsk Plc-spon Adr. (GSK) Share Price Forecast

Gsk Plc-spon Adr. (GSK) Price vs Consensus Price Target

Gsk Plc-spon Adr. (GSK) Share Price Forecast v/s Share Price Today

Gsk Plc-spon Adr. (GSK): Difference between Current Price & Median Forecasted Price

Gsk Plc-spon Adr. (GSK) Share Price Technical Analysis

50 Day Moving Average v/s Current Share Price

200 Day Moving Average v/s Current Share Price